share_log

Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38

Benzinga ·  May 15 09:17

Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price target from $50 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment